16

Comprehensive vocabulary flashcards covering antineoplastic classifications, administration precautions, adverse toxicities, and hematopoietic stem cell transplantation (HSCT) management and complications.

Synthesis Phase (Cell Cycle)

The phase of the cell cycle during which cellular DNA is replicated in order for normal and malignant cells to reproduce and proliferate.

Gemcitabine

An antineoplastic medication classified as a cell cycle-specific chemotherapy drug.

Cell Cycle-Nonspecific Agents

Chemotherapy drugs that exert cytotoxic effects on cells in any phase of the cell cycle, including the resting, nondividing phase (e.g., carboplatin).

Carboplatin

A platinum-based chemotherapy agent that acts as a cell cycle-nonspecific agent.

Antimetabolites

A major class of chemotherapy drugs based on mechanism of action that includes fluorouracil, used to treat multiple types of solid tumors.

Taxane Hypersensitivity Reaction Window

The timeframe during which anaphylaxis-type reactions are known to occur most frequently in patients receiving infusions of paclitaxel and docetaxel, specifically during the first infusion.

Hyaluronidase

The antidote used to treat the extravasation site immediately after stopping the infusion if an extravasation of a vinca alkaloid occurs or is suspected.

Cisplatin Toxicity Profile

Antineoplastic agent associated with adverse effects including peripheral neuropathy, ototoxicity, and renal toxicity, but not typically cutaneous rash.

"Wasabi Nose"

A transient nasal burning sensation known to be caused by administration of the chemotherapy agent cyclophosphamide.

Tumor Volume Cellular Kinetics

Cellular alterations that occur as a tumor mass increases in size, characterized by a decrease in the number of actively dividing cells.

Aromatase Inhibitors (AIs)

A class of hormonal agents utilized in breast cancer therapy to prevent estrogen production in the breast and other body tissues.

Subcutaneous/Intramuscular Antineoplastic Administration Guidelines

Nursing considerations requiring evaluation of the patient's platelet count prior to administration and the use of the smallest gauge needle possible.

Posttransplant Immunosuppression (Allogeneic HSCT)

Therapy prescribed following allogeneic hematopoietic stem cell transplantation to prevent donor T lymphocytes from mounting an immune response against the stem cell recipient.

HSCT Modality Determinant

The patient-specific factor that significantly impacts determination of the transplant type to undergo, specifically the underlying malignancy or nonmalignant hematologic disease.

Acute Graft-Versus-Host Disease (Cutaneous Presentation)

A post-allogeneic HSCT complication presenting within weeks of transplant with new-onset erythematous skin on the face, palms of the hands, and soles of the feet.

Hepatic Sinusoidal Obstruction Syndrome (SOS) Nursing Assessment

The routine assessment of daily weights to monitor for fluid retention and clinical worsening of sinusoidal obstruction.

Foscarnet

An antiviral agent frequently used to treat Cytomegalovirus (CMV) infection post-transplantation.

Autologous HSCT

A type of stem cell transplant utilizing the patient's own cells that can be effective in treating certain autoimmune diseases.

Idiopathic Pulmonary Interstitial Pneumonitis Prevention

Preventative measures in HSCT recipients that include the utilization of a filtered air system and CMV sero-negative blood products.

Acute GVHD, Overall Clinical Grade III

A clinical classification of graft-versus-host disease presenting post-transplant (such as day $+48$) with total bilirubin of $4\,\text{mg/dL}$ and greater than $1000\,\text{mL}$ of stool per day.

Hepatic SOS Risk Factors

Clinical factors predisposing patients to sinusoidal obstruction syndrome, notably pre-transplantation hepatotoxic drug therapy.

Pretransplant Conditioning Regimen

Pre-engraftment therapy administered to eradicate remaining malignancy and open spaces within the bone marrow.

GVHD Immunosuppressant Monitoring

A critical nursing intervention for managing both acute and chronic graft-versus-host disease by evaluating serum cyclosporine or tacrolimus levels.

Aspergillus species (Post-HSCT)

A fungal infectious complication that characteristically develops in HSCT recipients between $1$ and $4$ months following transplantation.

Streptococcus pneumoniae (Post-HSCT)

A late bacterial infectious complication that typically occurs in HSCT recipients between $4$ and $12$ months following transplantation.